Withania somnifera and COVID-19: Current evidence and future prospective

Document Type : Review Article

Authors

1 Department of cellular and molecular nutrition, faculty of nutritional sciences and dietetics, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Nursing, Tarbiat Modares University, Tehran, Iran.

3 Department of Medical-Surgical Care Nursing, School of Nursing and Midwifery Tehran University of Medical Sciences, Tehran, Iran

4 MSc in geriatric nursing, Yazd reproductive science institute (YRSI), Yazd, Iran.

5 University of Jordan, Faculty of Medicine, Amman, Jordan

Abstract

The most recent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged the health systems around the world. Currently, there is no definite treatment for COVID-19 and researchers are exploring herbal plant species. Withania Somnifera (WS) and its active ingredients may have potential benefits against COVID-19 activity and related cytokine storm. COVID-19 manifestations are not limited to the respiratory system and extend to vital body organs, a syndrome called multiple organ failure. WS also showed protective effects in different organs such as the lung, heart, liver, and kidneys. In this review, we aimed to summarize the pharmacological effects and underlying mechanisms of WS against COVID-19 and related complications. WS showed anti-inflammatory, antioxidant, hepatoprotective, cardioprotective, antifibrotic, anticancer, and immunomodulatory effects, mainly by downregulating NF-κB and related pathways. The suggested clinical benefits of WS for COVID-19 were investigated by clarifying their underlying mechanisms in this review.

Keywords


1.Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Science of the Total Environment. 2020;730:138996.
2.Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Current problems in cardiology. 2020;45(8):100618.
3.Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish journal of medical sciences. 2020;50(SI-1):620-32.
4.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033-4.
5.Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA internal medicine. 2020;180(9):1152-4.
6.Kadhom M, Al-Doori AN, Ahmed DS, Yousif E. Herbal medicine as an alternative method to treat and prevent COVID-19. Baghdad Journal of Biochemistry and Applied Biological Sciences. 2021;2(01):1-20.
7.Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional herbal medicine candidates as complementary treatments for COVID-19: a review of their mechanisms, pros and cons. Evidence-Based Complementary and Alternative Medicine. 2020;2020.
8.Chopra A, Gautam PC, Tillu G, Saluja M, Borse S, Sarmukaddam S, et al. Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine: A Study Protocol. medRxiv. 2021.
9.Yadav B, Rai A, Mundada PS, Singhal R, Rao B, Rana R, et al. Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):1-3.
10.Dhawan M, Parmar M, Sharun K, Tiwari R, Bilal M, Dhama K. Medicinal and therapeutic potential of withanolides from Withania somnifera against COVID-19. J Appl Pharm Sci. 2021;11:6-13.
11.John J. Therapeutic potential of Withania somnifera: a report on phyto-pharmacological properties. International Journal of Pharmaceutical sciences and research. 2014;5(6):2131-48.
12.Mir BA, Khazir J, Mir NA, Hasan T-u, Koul S. Botanical, chemical and pharmacological review of Withania somnifera (Indian ginseng): an ayurvedic medicinal plant. Indian J Drugs Dis. 2012;1(6):147-60.
13.Namdeo AG, Ingawale DK. Ashwagandha: Advances in plant biotechnological approaches for propagation and production of bioactive compounds. Journal of Ethnopharmacology. 2020:113709.
14.Gajbhiye NA, Makasana J, Kumar S. Accumulation of three important bioactive compounds in different plant parts of Withania somnifera and its determination by the LC–ESI-MS-MS (MRM) method. Journal of chromatographic science. 2015;53(10):1749-56.
15.Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Frontiers in immunology. 2020;11:1648.
16.Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open biology. 2020;10(9):200160.
17.Sikandan A, Shinomiya T, Nagahara Y. Ashwagandha root extract exerts anti‑inflammatory effects in HaCaT cells by inhibiting the MAPK/NF‑κB pathways and by regulating cytokines. International journal of molecular medicine. 2018;42(1):425-34.
18.Grunz-Borgmann E, Mossine V, Fritsche K, Parrish AR. Ashwagandha attenuates TNF-α-and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells. BMC complementary and alternative medicine. 2015;15(1):1-8.
19.Bhasin S, Singh M, Singh D. Review on bioactive metabolites of Withania somnifera.(L.) Dunal and its pharmacological significance. Journal of Pharmacognosy and Phytochemistry. 2019;8(3):3906-9.
20.Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, et al. A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sciences. 2007;80(16):1525-38.
21.Kour K, Pandey A, Suri K, Satti N, Gupta K, Bani S. Restoration of stress-induced altered T cell function and corresponding cytokines patterns by Withanolide A. International immunopharmacology. 2009;9(10):1137-44.
22.Sun GY, Li R, Cui J, Hannink M, Gu Z, Fritsche KL, et al. Withania somnifera and its withanolides attenuate oxidative and inflammatory responses and up-regulate antioxidant responses in BV-2 microglial cells. Neuromolecular medicine. 2016;18(3):241-52.
23.Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. British journal of pharmacology. 2005;144(7):961-71.
24.SoRelle J, Itoh T, Peng H, Kanak M, Sugimoto K, Matsumoto S, et al. Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia. 2013;56(4):814-24.
25.Batumalaie K, Amin MA, Murugan DD, Sattar MZA, Abdullah NA. Withaferin A protects against palmitic acid-induced endothelial insulin resistance and dysfunction through suppression of oxidative stress and inflammation. Scientific reports. 2016;6(1):1-11.
26.Maitra R, Porter MA, Huang S, Gilmour BP. Inhibition of NFκB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. Journal of Inflammation. 2009;6(1):1-5.
27.Martorana F, Guidotti G, Brambilla L, Rossi D. Withaferin A inhibits nuclear factor-κB-dependent pro-inflammatory and stress response pathways in the astrocytes. Neural plasticity. 2015;2015.
28.Fang R, Wang C, Jiang Q, Lv M, Gao P, Yu X, et al. NEMO–IKKβ are essential for IRF3 and NF-κB activation in the cGAS–STING pathway. The Journal of Immunology. 2017;199(9):3222-33.
29.Guo R, Gan L, Lau WB, Yan Z, Xie D, Gao E, et al. Withaferin A prevents myocardial ischemia/reperfusion injury by upregulating AMP-activated protein kinase-dependent B-cell lymphoma2 signaling. Circulation Journal. 2019;83(8):1726-36.
30.Challa AA, Vukmirovic M, Blackmon J, Stefanovic B. Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. 2012.
31.Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor-α-induced expression of cell adhesion molecules by inactivation of Akt and NF-κB in human pulmonary epithelial cells. International immunopharmacology. 2009;9(5):614-9.
32.Gao S, Li H, Zhou X, You J, Tu D, Xia G, et al. Withaferin A attenuates lipopolysaccharide-induced acute lung injury in neonatal rats. Cellular and Molecular Biology. 2015;61(3):102-6.
33.Gupta A, Singh S. Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharmaceutical biology. 2014;52(3):308-20.
34.Saleem S, Muhammad G, Hussain MA, Altaf M, Bukhari SNA. Withania somnifera L.: Insights into the phytochemical profile, therapeutic potential, clinical trials, and future prospective. Iranian Journal of Basic Medical Sciences. 2020;23(12):1501.
35.Krutika J, Tavhare S, Panara K, Kumar P, Karra N. Studies of ashwagandha (Withania somnifera dunal). Int J Pharm Biol Arch. 2016;7(1):1-11.
36.Berghe WV, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochemical pharmacology. 2012;84(10):1282-91.
37.Kumar V, Dey A, Hadimani MB, Marcovic T, Emerald M. Chemistry and pharmacology of Withania somnifera: An update. CELLMED. 2015;5(1):1.-.13.
38.Tillu G, Chaturvedi S, Chopra A, Patwardhan B. Public health approach of ayurveda and yoga for COVID-19 prophylaxis. The Journal of Alternative and Complementary Medicine. 2020;26(5):360-4.
39.McCord JM, Hybertson BM, Cota-Gomez A, Geraci KP, Gao B. Nrf2 activator PB125® as a potential therapeutic agent against COVID-19. Antioxidants. 2020;9(6):518.
40.Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. Journal of molecular histology. 2020:1-16.
41.Roshdy A, Zaher S, Fayed H, Coghlan JG. COVID-19 and the heart: a systematic review of cardiac autopsies. Frontiers in cardiovascular medicine. 2020;7.
42.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
43.alvatici M, Barbieri B, Cioffi SMG, Morenghi E, Leone FP, Maura F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. Biomarkers. 2020;25(8):634-40.
44.Hamza A, Amin A, Daoud S. The protective effect of a purified extract of Withania somnifera against doxorubicin-induced cardiac toxicity in rats. Cell biology and toxicology. 2008;24(1):63-73.
45.Khalil M, Ahmmed I, Ahmed R, Tanvir E, Afroz R, Paul S, et al. Amelioration of isoproterenol-induced oxidative damage in rat myocardium by Withania somnifera leaf extract.  BioMed research international. 2015;2015.
46.Tripathi R, Salve B, Petare A, Raut A, Rege N. Effect of Withania somnifera on physical and cardiovascular performance induced by physical stress in healthy human volunteers. Int J Basic Clin Pharmacol. 2016;5:2510-6.
47.Kushwaha S, Betsy A, Chawla P. Effect of Ashwagandha (Withania somnifera) root powder supplementation in treatment of hypertension. Studies on Ethno-Medicine. 2012;6(2):111-5.
48.Pathak P, Shukla P, Kanshana JS, Jagavelu K, Sangwan NS, Dwivedi AK, et al. Standardized root extract of Withania somnifera and Withanolide A exert moderate vasorelaxant effect in the rat aortic rings by enhancing nitric oxide generation. Journal of Ethnopharmacology. 2021:114296.
49.Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Della Casa G, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? The Lancet Respiratory Medicine. 2020;8(8):750-2.
50.Nielsen SH, Willumsen N, Leeming DJ, Daniels SJ, Brix S, Karsdal MA, et al. Serological assessment of activated fibroblasts by alpha-smooth muscle actin (α-SMA): a noninvasive biomarker of activated fibroblasts in lung disorders. Translational oncology. 2019;12(2):368-74.
51.Nagashima S, Mendes MC, Camargo Martins AP, Borges NH, Godoy TM, Miggiolaro AFRdS, et al. Endothelial dysfunction and thrombosis in patients with COVID-19—brief report. Arteriosclerosis, thrombosis, and vascular biology. 2020;40(10):2404-7.
52.Kaur G, Singh N, Samuel SS, Bora HK, Sharma S, Pachauri SD, et al. Withania somnifera shows a protective effect in monocrotaline-induced pulmonary hypertension. Pharmaceutical biology. 2015;53(1):147-57.
53.Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. Journal of clinical medicine. 2020;9(5):1417.
54.Zhao G, Su Y, Sun X, Cui X, Dang L, Zhao L, et al. A comparative study of the laboratory features of COVID‐19 and other viral pneumonias in the recovery stage. Journal of Clinical Laboratory Analysis. 2020;34(10):e23483.
55.Bastug A, Bodur H, Erdogan S, Gokcinar D, Kazancioglu S, Kosovali BD, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. International immunopharmacology. 2020;88:106950.
56.Sharma V, Sharma S, Pracheta PR, Sharma S. Therapeutic efficacy of Withania somnifera root extract in the regulation of lead nitrate induced nephrotoxicity in Swiss albino mice. J Pharm Res. 2011;4(3):755-75.
57.Govindappa PK, Gautam V, Tripathi SM, Sahni YP, Raghavendra HLS. Effect of Withania somnifera on gentamicin induced renal lesions in rats. Revista Brasileira de Farmacognosia. 2019;29:234-40.
58.Vasavan SS, Jagadesan V, Sivanesan S, Rajagopalan V. Protective effect of Withania somnifera on nandrolone decanoate-induced biochemical alterations and hepatorenal toxicity in wistar rats. Pharmacognosy Magazine. 2020;16(68):218.
59.Rasheed A, Younus N, Waseem N, Badshsah M, editors. Protective Effect of Withania Somnifera Root Extract Against Cisplatin Induced Nephrotoxicity Through Renal Function Analysis in Albino Wistar Rats. Med Forum; 2020.
60.Akhtar F, Azhar M, Aslam M, Javed K. Nephroprotective Effect of Asgand Powder (Withania somnifera Dunal) on Cisplatin Induced Renal Injury in Rats. Journal of Drug Delivery and Therapeutics. 2020;10(6-s):22-5.
61.Vedi M, Rasool M, Sabina EP. Protective effect of administration of Withania somifera against bromobenzene induced nephrotoxicity and mitochondrial oxidative stress in rats. Renal failure. 2014;36(7):1095-103.
62.Kumar-M P, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, et al. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatology international. 2020;14(5):711-22.
63.Mansour HH, Hafez HF. Protective effect of Withania somnifera against radiation-induced hepatotoxicity in rats. Ecotoxicology and environmental safety. 2012;80:14-9.
64.Elsemelawy SAE, Tag Al Deen R. Effect of Feeding Cake Fortified with Different Concentrations of Ashwagandha Root against Sodium Arsenite Toxicity in Male Rats. Bulletin of the National Nutrition Institute of the Arab Republic of Egypt. 2016;47(2):1-22.
65.Sabina EP, Rasool M, Vedi M, Navaneethan D, Ravichander M, Parthasarthy P, et al. Hepatoprotective and antioxidant potential of Withania somnifera against paracetamol-induced liver damage in rats. Int J Pharm Pharm Sci. 2013;5(2):648-51.
66.Bhattacharya A, Ramanathan M, Ghosal S, Bhattacharya S. Effect of Withania somnifera glycowithanolides on iron‐induced hepatotoxicity in rats. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2000;14(7):568-70.
67.Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clinica Chimica Acta. 2020;508:110-4.
68.Kumar R, Rai J, Kajal N, Devi P. Comparative study of effect of Withania somnifera as an adjuvant to DOTS in patients of newly diagnosed sputum smear positive pulmonary tuberculosis. Indian Journal of Tuberculosis. 2018;65(3):246-51.
69.Khan B, Ahmad SF, Bani S, Kaul A, Suri K, Satti N, et al. Augmentation and proliferation of T lymphocytes and Th-1 cytokines by Withania somnifera in stressed mice. International immunopharmacology. 2006;6(9):1394-403.
70.Mikolai J, Erlandsen A, Murison A, Brown KA, Gregory WL, Raman-Caplan P, et al. In vivo effects of Ashwagandha (Withania somnifera) extract on the activation of lymphocytes. The Journal of Alternative and Complementary Medicine. 2009;15(4):423-30.
71.Latheef SK, Dhama K, Samad HA, Wani MY, Kumar MA, Palanivelu M, et al. Immunomodulatory and prophylactic efficacy of herbal extracts against experimentally induced chicken infectious anaemia in chicks: assessing the viral load and cell mediated immunity. Virusdisease. 2017;28(1):115-20.
72.Adi BSABS, Rami SRRES, Reddy E. An open clinical study on the efficacy of Withania somnifera mother tincture in the management of hyperlipidemia. International Journal of Indigenous Herbs and Drugs. 2019:1-6.
73.Zhao H, Gao Z, Xie S, Han X, Sun Q. Withaferin A attenuates ovalbumin induced airway inflammation. injury. 2019;5:6.
74.Bale S, Venkatesh P, Sunkoju M, Godugu C. An adaptogen: withaferin A ameliorates in vitro and in vivo pulmonary fibrosis by modulating the interplay of fibrotic, matricelluar proteins, and cytokines. Frontiers in pharmacology. 2018;9:248.
75.Pérez-Gómez J, Villafaina S, Adsuar JC, Merellano-Navarro E, Collado-Mateo D. Effects of Ashwagandha (Withania somnifera) on VO2max: a systematic review and meta-analysis. Nutrients. 2020;12(4):1119.
76.Chand G, Singh P. POSSIBLE RETRIEVAL OF ORGANOCHLORINE INDUCED RENAL TOXICITY IN FISH BY AQUEOUS ROOT EXTRACT OF WITHANIA SOMNIFERA: IN VIVO STUDY. International Journal of Pharmaceutical Sciences and Research. 2016;7(6).
77.Davis L, Kuttan G. Immunomodulatory activity of Withania somnifera. Journal of ethnopharmacology. 2000;71(1-2):193-200.